IL17A and tuberculosis: Initially developed for tuberculosis control, rBCG-LTAK63 demonstrated superior efficacy in eliciting a robust Th1/Th17 response, with increased IFN-γ, TNF-α, IL-2, and IL-17 production compared to conventional BCG 13.